ATLX-1282
Not specified (focus areas are neurodegeneration/oncology)
Key Facts
About Alchemab Therapeutics
Alchemab Therapeutics, founded in 2019 and based in Cambridge, UK, has developed a unique platform that reverse-engineers protective immunity from resilient patient populations to discover novel antibody therapeutics. The company's approach identifies common antibody signatures among individuals who naturally resist or overcome severe diseases, enabling the development of therapeutics with a potentially high probability of success. With a lead program, ATLX-1282, now in Phase 1 and a focus on neurodegeneration and oncology, Alchemab is positioning itself at the intersection of computational biology and antibody drug discovery. The company is privately held, backed by venture capital, and is actively expanding its business development efforts.
View full company profile